Click Therapeutics

News

Boehringer transfers schizophrenia DTx selling rights to Cli...

Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.

Digital

Is DTx finally reaching drug-like efficacy? A Q&A with David...

Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.

News

Boehringer, Click DTx for schizophrenia clears pivotal trial

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.

News

Click, Boehringer DTx for schizophrenia passes phase 3 test

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.

News

App to support people with depression launches in GB

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.

News

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

Boehringer transfers schizophrenia DTx selling rights to Cli...

Is DTx finally reaching drug-like efficacy? A Q&A with David...

Boehringer, Click DTx for schizophrenia clears pivotal trial

Click, Boehringer DTx for schizophrenia passes phase 3 test

App to support people with depression launches in GB

FDA clears first migraine DTx from Click Therapeutics

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Click Therapeutics

Editor's Picks